Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 1/20 | 0.57 |
| ▸ | DRD3 | P35462 | 1/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.53 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
| ▸ | HRH2 | P25021 | 3/20 | 0.50 |
| ▸ | HRH1 | P35367 | 3/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | BRD4 | O60885 | 1/20 | 0.49 |
| ▸ | AR | P10275 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3061663 | 0.86 | EPHX2 (0.54) | HRH3KCNH2CYP3A4CYP2C9EPHX2 | |
| SCHEMBL25933903 | 0.84 | HRH3 (0.66) | DRD3HRH3KCNH2CYP3A4CYP2C9 | |
| SCHEMBL4672481 | 0.82 | HRH3 (0.80) | HRH3KCNH2CYP3A4CYP2C9 | |
| SCHEMBL748867 | 0.81 | EPHX2 (0.49) | DRD3EPHX2HRH2HRH1AR | |
| SCHEMBL3566263 | 0.79 | AURKA (0.46) | MCHR1DRD3HRH3CYP4F2CYP4A11 | |
| SCHEMBL10200150 | 0.79 | DRD3 (0.68) | DRD3HRH3CYP4F2CYP4A11EPHX2 | |
| SCHEMBL19988066 | 0.79 | BRD4 (0.56) | MCHR1DRD3HRH3KCNH2BRD4 | |
| SCHEMBL17477293 | 0.79 | BRD4 (0.56) | MCHR1DRD3HRH3KCNH2BRD4 | |
| SCHEMBL18837292 | 0.78 | DRD3 (0.67) | DRD3HRH3CYP4F2CYP4A11EPHX2 | |
| SCHEMBL12376853 | 0.76 | MAOB (0.58) | DRD3HRH3KCNH2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102388048-B | Triazolo [4,3-b] pyridazine derivatives and their uses for prostate cancer | ASTRAZENECA AB | 2014-07-30 | — | — | CN | disclosed |
| US-20130203714-A1 | CHEMICAL COMPOUNDS - 643 | ASTRAZENECA R&D (SE) | 2013-08-08 | — | — | US | disclosed |
| EP-2396333-B1 | TRIAZOLO[4,3-B]PYRIDAZINE DERIVATIVES AND THEIR USES FOR PROSTATE CANCER | ASTRAZENECA AB (SE) | 2013-07-03 | — | — | EP | disclosed |
| US-8258140-B2 | Chemical compounds—643 | ASTRAZENECA AB (SE) | 2012-09-04 | — | — | US | disclosed |
| CN-102388048-A | Triazolo [4,3-b] pyridazine derivatives and their uses for prostate cancer | ASTRAZENECA AB | 2012-03-21 | — | — | CN | disclosed |
| EP-2396333-A1 | TRIAZOLO [4,3-B]PYRIDAZINE DERIVATIVES AND THEIR USES FOR PROSTATE CANCER | AstraZeneca AB (SE) | 2011-12-21 | — | — | EP | disclosed |
| US-20100267699-A1 | CHEMICAL COMPOUNDS - 643 | ASTRAZENECA R&D | 2010-10-21 | — | — | US | disclosed |
| WO-2010092371-A1 | TRIAZOLO [4,3-B] PYRIDAZINE DERIVATIVES AND THEIR USES FOR PROSTATE CANCER | ASTRAZENECA AB (SE) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203714-A1 | CHEMICAL COMPOUNDS - 643 | AR, KLK3, ESRRA | MCHR1 698/4885DRD3 855/4885HRH3 1705/4885 |
| US-20100267699-A1 | CHEMICAL COMPOUNDS - 643 | AR, KLK3, ESRRA | MCHR1 648/4885DRD3 908/4885HRH3 1729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.